ResearcherCanget Biotekpharma, LlcNo recent work listed
Fengzhi Li
Matched on ORCID iD 0000-0002-2299-7951; OpenAlex author ID A5027674029; NIH RePORTER profile ID 8345026. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 2)
- Trials
- 0
- Grants
- 4
- Labs led
- 1
- Collaborators
- 5
2015: 1 grant · 2016: 1 grant · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 grant · 2021: none · 2022: 1 paper · 2023: 1 grant
Papers 3
- FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras agai… Last author DOI 10.1002/ctm2.881↗
- An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. Last author DOI 10.1186/s13046-018-0899-8↗
- Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition. First author PMID 30555743↗
Grants 4
- Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials R43CA275410↗
- Validation of Targets as Biomarkers for Targeted Pancreatic Cancer Therapy AWARD pancan:2020-fengzhi-li-phd-validation-of-targets-as-biomarkers-for-
- A novel regimen to target both pancreatic cancer K-ras and antiapoptotic proteins R03CA182552↗
- An inhibitor of multiple anti-apoptotic gene products for pancreatic cancer R21CA180764↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xiang Ling · 1 shared grant, 2023 · strength 0.77
- Xiang Ling · 2 shared papers, 2018–2022 · strength 0.24
- Paper FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to cont… DOI 10.1002/ctm2.881↗
- Paper An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment res… DOI 10.1186/s13046-018-0899-8↗
- Thangaiyan Rabi · 1 shared paper, 2018 · strength 0.17
- Christos K Fountzilas · 1 shared paper, 2022 · strength 0.16
- Xinjiang Wang · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.